Monte Rosa Therapeutics (GLUE) EBITDA Margin (2024 - 2026)
Monte Rosa Therapeutics' EBITDA Margin was -526.53% in Q2 2026, down 468.63 percentage points from -57.90% a year earlier but up 613.73 percentage points from the prior quarter.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) EBITDA Margin (2024 - 2026) Analysis & Trends
On a trailing twelve-month basis, Monte Rosa Therapeutics' EBITDA Margin was -604.61% through Jun 30, 2026, down 617.70 percentage points year-over-year; for FY2025, it was -37.04%, up 59.48 percentage points from FY2024.
- In earlier years, EBITDA Margin was -96.52% in FY2024.
- Quarterly EBITDA Margin has moved between -3105.92% (Q1 2024) and 54.26% (Q1 2025) over five years.
- Compared with a year earlier, EBITDA Margin has declined for three straight quarters, with an average year-over-year change of +62.97 percentage points over the last six quarters.
- Per Business Quant data, GLUE's EBITDA Margin in the three quarters before Q2 2026 was -1140.26% (Q1 2026), -1711.00% (Q4 2025) and -241.85% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Monte Rosa Therapeutics | 998.00 Mn | 409.81 Mn | - | -526.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -526.53% |
| Mar 31, 2026 | -1,140.26% |
| Dec 31, 2025 | -1,711.00% |
| Sep 30, 2025 | -241.85% |
| Jun 30, 2025 | -57.90% |
| Mar 31, 2025 | 54.26% |
| Dec 31, 2024 | 24.84% |
| Sep 30, 2024 | -265.02% |
| Jun 30, 2024 | -651.37% |
| Mar 31, 2024 | -3,105.92% |
API Access
Monte Rosa Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GLUE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "GLUE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GLUE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();